Understanding the 2024 annual performance of Stone Pharmaceutical (02616) in one picture: licensing fees exceeded 0.2321 billion yuan, and the commercialization path is increasingly clear.

In 2024, CSTONE PHARMA-B (02616) showed a significant improvement in financial performance year-on-year: total revenue during the period was 0.4072 billion yuan, of which royalties and licensing fees amounted to 0.2321 billion yuan; the loss for the year decreased by 71.5%.

Zhitong FinanceMar 28 02:41 ET

Express News | CStone Pharmaceuticals Announces 2024 Annual Results and Recent Business Progress

ReutersMar 27 07:55 ET

Express News | CStone Pharmaceuticals - Loss for Year Was RMB91.2 Mln

ReutersMar 27 04:32 ET

CSTONE PHARMA-B: ANNOUNCEMENT OF ANNUAL RESULTSFOR THE YEAR ENDED DECEMBER 31, 2024

HKEXMar 27 04:30 ET · Announcements

Hong Kong Stock Concept Tracking | The USA AACR Annual Meeting is about to be held, and domestic Innovative Drugs are accelerating the construction of Global competitiveness (attached concept stocks).

The AACR Annual Meeting will be held in Chicago, USA from April 25 to 30, 2025, local time.

Zhitong FinanceMar 26 22:50 ET

CSTONE PHARMA-B (02616.HK) made a stunning appearance at AACR 2025 with five latest research achievements.

Gelonghui, March 26丨CSTONE PHARMA-B (02616.HK) announced that from April 25 to 30, 2025, the American Association for Cancer Research (AACR) annual meeting will be held in Chicago. The latest preclinical research results of CSTONE PHARMA's five independently developed Innovative Drugs will be showcased at this international top academic stage, including the triple antibody CS2009, the dual antibody CS2011, and three innovative ADC molecules CS5006, CS5007, and CS5005 from the company's own antibody-drug conjugate (ADC) platform. The related research abstracts will be presented on April 2025, Eastern Time.

Gelonghui FinanceMar 25 20:06 ET